{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"170"}],"title":"Detected"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"title":"Not Detected"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"9"}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"190"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"136"},{"groupId":"OG002","value":"122"}],"title":"Detected"},{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"6"}],"title":"Not Detected"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"159"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"105"}],"title":"Detected"},{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"6"}],"title":"Not Detected"},{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"113"}],"units":"Participants"}],"title":"Cycle 2 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"59"}],"title":"Detected"},{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"}],"title":"Not Detected"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"111"},{"groupId":"OG002","value":"63"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"99"}],"title":"Detected"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"title":"Not Detected"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"102"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"190"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"description":"ctDNA status was classified as follows; detected: overall variant allele frequency (VAF) was greater than zero, not detected: overall VAF equalled zero, and not evaluable: overall VAF could not be calculated. The VAF was defined as percentage of deoxyribonucleic acid (DNA) reads at a specific position that show a genetic variant instead of the normal (reference) sequence. The number of participants as per their ctDNA status (detected, not detected and not evaluable) have been reported in this outcome measure.","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"Phase 3: Arm A [EC]"},{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG001","title":"Phase 3: Arm B [EC + mFOLFOX6]"},{"description":"Participants received standard of care (SOC) chemotherapy per Investigator's choice: mFOLFOX6 with or without bevacizumab or FOLFOXIRI with or without bevacizumab or CAPOX with or without bevacizumab. Bevacizumab was optional and it was given per prescribing instructions of treating physician. mFOLFOX6 (28-day Cycle): fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W; FOLFOXIRI (28-day Cycle): fluorouracil 2400 or 3200 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W (per local standard of care); leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 165 mg/m\\^2 as IV infusion for 90 minutes Q2W; CAPOX (21-day Cycle): capecitabine 1000 mg/m\\^2 oral tablet twice daily on Days 1-14 and oxaliplatin 130 mg/m\\^2 IV infusion for 120 minutes Q3W.","id":"OG002","title":"Phase 3: Arm C [Standard of Care Chemotherapy, Control Arm]"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The biomarker tumor tissue analysis set was defined as participants from the safety analysis set who had a tumor biomarker assessment at baseline. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure and \"Number Analyzed\" signifies participants evaluable for specified rows.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 15, Cycle 7 Day 1 and End of Treatment (anytime till maximum of 37.25 months)","title":"Phase 3: Number of Participants According to Circulating Tumor Deoxyribonucleic Acid (ctDNA) Status","type":"SECONDARY","unitOfMeasure":"Participants"}